First Dallas Securities Inc. Sells 606 Shares of Johnson & Johnson $JNJ

First Dallas Securities Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.4% in the 2nd quarter, HoldingsChannel reports. The fund owned 10,573 shares of the company’s stock after selling 606 shares during the quarter. First Dallas Securities Inc.’s holdings in Johnson & Johnson were worth $1,615,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Greenup Street Wealth Management LLC grew its holdings in Johnson & Johnson by 3.1% in the 2nd quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after buying an additional 60 shares in the last quarter. Ellis Investment Partners LLC lifted its holdings in shares of Johnson & Johnson by 0.7% during the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after buying an additional 62 shares in the last quarter. Cypress Wealth Services LLC boosted its position in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after acquiring an additional 62 shares during the period. Horizon Bancorp Inc. IN grew its stake in shares of Johnson & Johnson by 11.2% in the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock valued at $97,000 after acquiring an additional 64 shares in the last quarter. Finally, Global Strategic Investment Solutions LLC increased its position in Johnson & Johnson by 3.5% during the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after acquiring an additional 65 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $186.50 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock’s 50-day simple moving average is $184.25 and its 200 day simple moving average is $168.80. The firm has a market capitalization of $449.34 billion, a PE ratio of 18.00, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on JNJ. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Bank of America increased their price target on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Citigroup raised their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. UBS Group upped their target price on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Finally, Stifel Nicolaus raised their price target on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.